Report cover image

Global Adult Non Hodgkin Lymphoma Treatment Market Research Report 2025(Status and Outlook)

Publisher Bosson Research
Published Nov 07, 2025
Length 159 Pages
SKU # BOSS20731970

Description

Report Overview

Non-Hodgkin lymphoma (NHL) is an umbrella term for a group of independent diseases with strong heterogeneity

The global Adult Non Hodgkin Lymphoma Treatment market size was estimated at USD 8861.0 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.40% during the forecast period.

This report provides a deep insight into the global Adult Non Hodgkin Lymphoma Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Adult Non Hodgkin Lymphoma Treatment Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Adult Non Hodgkin Lymphoma Treatment market in any manner.

Global Adult Non Hodgkin Lymphoma Treatment Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Janssen Pharma_x000D_

Genentech, Inc._x000D_

CELGENE CORPORATION_x000D_

Merck & Co.,Inc._x000D_

Kyowa Kirin Co., Ltd._x000D_

AbbVie Inc._x000D_

Sanofi_x000D_

Takeda Pharmaceutical Company_x000D_

AstraZeneca_x000D_

Bayer AGNovartis AG_x000D_

Kite Pharma, Inc_x000D_

Spectrum Pharmaceuticals, Inc._x000D_

Teva Pharmaceutical lndustries Ltd._x000D_

Bristol Myers Squibb Company

Market Segmentation (by Type)

B Cell_x000D_

T Cell_x000D_

NK/T Cells

Market Segmentation (by Application)

Hospital_x000D_

Clinic

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Adult Non Hodgkin Lymphoma Treatment Market

Overview of the regional outlook of the Adult Non Hodgkin Lymphoma Treatment Market:

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Adult Non Hodgkin Lymphoma Treatment Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Adult Non Hodgkin Lymphoma Treatment, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

Table of Contents

159 Pages
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Adult Non Hodgkin Lymphoma Treatment
1.2 Key Market Segments
1.2.1 Adult Non Hodgkin Lymphoma Treatment Segment by Type
1.2.2 Adult Non Hodgkin Lymphoma Treatment Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Adult Non Hodgkin Lymphoma Treatment Market Overview
2.1 Global Market Overview
2.1.1 Global Adult Non Hodgkin Lymphoma Treatment Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Adult Non Hodgkin Lymphoma Treatment Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Adult Non Hodgkin Lymphoma Treatment Market Competitive Landscape
3.1 Company Assessment Quadrant
3.2 Global Adult Non Hodgkin Lymphoma Treatment Product Life Cycle
3.3 Global Adult Non Hodgkin Lymphoma Treatment Sales by Manufacturers (2020-2025)
3.4 Global Adult Non Hodgkin Lymphoma Treatment Revenue Market Share by Manufacturers (2020-2025)
3.5 Adult Non Hodgkin Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Adult Non Hodgkin Lymphoma Treatment Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Adult Non Hodgkin Lymphoma Treatment Market Competitive Situation and Trends
3.8.1 Adult Non Hodgkin Lymphoma Treatment Market Concentration Rate
3.8.2 Global 5 and 10 Largest Adult Non Hodgkin Lymphoma Treatment Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 Adult Non Hodgkin Lymphoma Treatment Industry Chain Analysis
4.1 Adult Non Hodgkin Lymphoma Treatment Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Adult Non Hodgkin Lymphoma Treatment Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Adult Non Hodgkin Lymphoma Treatment Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy – April 2025
5.6.3 Global Trade Frictions and Their Impacts to Adult Non Hodgkin Lymphoma Treatment Market
5.7 ESG Ratings of Leading Companies
6 Adult Non Hodgkin Lymphoma Treatment Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Adult Non Hodgkin Lymphoma Treatment Sales Market Share by Type (2020-2025)
6.3 Global Adult Non Hodgkin Lymphoma Treatment Market Size Market Share by Type (2020-2025)
6.4 Global Adult Non Hodgkin Lymphoma Treatment Price by Type (2020-2025)
7 Adult Non Hodgkin Lymphoma Treatment Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Adult Non Hodgkin Lymphoma Treatment Market Sales by Application (2020-2025)
7.3 Global Adult Non Hodgkin Lymphoma Treatment Market Size (M USD) by Application (2020-2025)
7.4 Global Adult Non Hodgkin Lymphoma Treatment Sales Growth Rate by Application (2020-2025)
8 Adult Non Hodgkin Lymphoma Treatment Market Sales by Region
8.1 Global Adult Non Hodgkin Lymphoma Treatment Sales by Region
8.1.1 Global Adult Non Hodgkin Lymphoma Treatment Sales by Region
8.1.2 Global Adult Non Hodgkin Lymphoma Treatment Sales Market Share by Region
8.2 Global Adult Non Hodgkin Lymphoma Treatment Market Size by Region
8.2.1 Global Adult Non Hodgkin Lymphoma Treatment Market Size by Region
8.2.2 Global Adult Non Hodgkin Lymphoma Treatment Market Size Market Share by Region
8.3 North America
8.3.1 North America Adult Non Hodgkin Lymphoma Treatment Sales by Country
8.3.2 North America Adult Non Hodgkin Lymphoma Treatment Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Adult Non Hodgkin Lymphoma Treatment Sales by Country
8.4.2 Europe Adult Non Hodgkin Lymphoma Treatment Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Adult Non Hodgkin Lymphoma Treatment Sales by Region
8.5.2 Asia Pacific Adult Non Hodgkin Lymphoma Treatment Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Adult Non Hodgkin Lymphoma Treatment Sales by Country
8.6.2 South America Adult Non Hodgkin Lymphoma Treatment Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Adult Non Hodgkin Lymphoma Treatment Sales by Region
8.7.2 Middle East and Africa Adult Non Hodgkin Lymphoma Treatment Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 Adult Non Hodgkin Lymphoma Treatment Market Production by Region
9.1 Global Production of Adult Non Hodgkin Lymphoma Treatment by Region(2020-2025)
9.2 Global Adult Non Hodgkin Lymphoma Treatment Revenue Market Share by Region (2020-2025)
9.3 Global Adult Non Hodgkin Lymphoma Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Adult Non Hodgkin Lymphoma Treatment Production
9.4.1 North America Adult Non Hodgkin Lymphoma Treatment Production Growth Rate (2020-2025)
9.4.2 North America Adult Non Hodgkin Lymphoma Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Adult Non Hodgkin Lymphoma Treatment Production
9.5.1 Europe Adult Non Hodgkin Lymphoma Treatment Production Growth Rate (2020-2025)
9.5.2 Europe Adult Non Hodgkin Lymphoma Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Adult Non Hodgkin Lymphoma Treatment Production (2020-2025)
9.6.1 Japan Adult Non Hodgkin Lymphoma Treatment Production Growth Rate (2020-2025)
9.6.2 Japan Adult Non Hodgkin Lymphoma Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Adult Non Hodgkin Lymphoma Treatment Production (2020-2025)
9.7.1 China Adult Non Hodgkin Lymphoma Treatment Production Growth Rate (2020-2025)
9.7.2 China Adult Non Hodgkin Lymphoma Treatment Production, Revenue, Price and Gross Margin (2020-2025)
10 Key Companies Profile
10.1 Janssen Pharma_x000D_
10.1.1 Janssen Pharma_x000D_ Basic Information
10.1.2 Janssen Pharma_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.1.3 Janssen Pharma_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.1.4 Janssen Pharma_x000D_ Business Overview
10.1.5 Janssen Pharma_x000D_ SWOT Analysis
10.1.6 Janssen Pharma_x000D_ Recent Developments
10.2 Genentech, Inc._x000D_
10.2.1 Genentech, Inc._x000D_ Basic Information
10.2.2 Genentech, Inc._x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.2.3 Genentech, Inc._x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.2.4 Genentech, Inc._x000D_ Business Overview
10.2.5 Genentech, Inc._x000D_ SWOT Analysis
10.2.6 Genentech, Inc._x000D_ Recent Developments
10.3 CELGENE CORPORATION_x000D_
10.3.1 CELGENE CORPORATION_x000D_ Basic Information
10.3.2 CELGENE CORPORATION_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.3.3 CELGENE CORPORATION_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.3.4 CELGENE CORPORATION_x000D_ Business Overview
10.3.5 CELGENE CORPORATION_x000D_ SWOT Analysis
10.3.6 CELGENE CORPORATION_x000D_ Recent Developments
10.4 Merck and Co.,Inc._x000D_
10.4.1 Merck and Co.,Inc._x000D_ Basic Information
10.4.2 Merck and Co.,Inc._x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.4.3 Merck and Co.,Inc._x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.4.4 Merck and Co.,Inc._x000D_ Business Overview
10.4.5 Merck and Co.,Inc._x000D_ Recent Developments
10.5 Kyowa Kirin Co., Ltd._x000D_
10.5.1 Kyowa Kirin Co., Ltd._x000D_ Basic Information
10.5.2 Kyowa Kirin Co., Ltd._x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.5.3 Kyowa Kirin Co., Ltd._x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.5.4 Kyowa Kirin Co., Ltd._x000D_ Business Overview
10.5.5 Kyowa Kirin Co., Ltd._x000D_ Recent Developments
10.6 AbbVie Inc._x000D_
10.6.1 AbbVie Inc._x000D_ Basic Information
10.6.2 AbbVie Inc._x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.6.3 AbbVie Inc._x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.6.4 AbbVie Inc._x000D_ Business Overview
10.6.5 AbbVie Inc._x000D_ Recent Developments
10.7 Sanofi_x000D_
10.7.1 Sanofi_x000D_ Basic Information
10.7.2 Sanofi_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.7.3 Sanofi_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.7.4 Sanofi_x000D_ Business Overview
10.7.5 Sanofi_x000D_ Recent Developments
10.8 Takeda Pharmaceutical Company_x000D_
10.8.1 Takeda Pharmaceutical Company_x000D_ Basic Information
10.8.2 Takeda Pharmaceutical Company_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.8.3 Takeda Pharmaceutical Company_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.8.4 Takeda Pharmaceutical Company_x000D_ Business Overview
10.8.5 Takeda Pharmaceutical Company_x000D_ Recent Developments
10.9 AstraZeneca_x000D_
10.9.1 AstraZeneca_x000D_ Basic Information
10.9.2 AstraZeneca_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.9.3 AstraZeneca_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.9.4 AstraZeneca_x000D_ Business Overview
10.9.5 AstraZeneca_x000D_ Recent Developments
10.10 Bayer AGNovartis AG_x000D_
10.10.1 Bayer AGNovartis AG_x000D_ Basic Information
10.10.2 Bayer AGNovartis AG_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.10.3 Bayer AGNovartis AG_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.10.4 Bayer AGNovartis AG_x000D_ Business Overview
10.10.5 Bayer AGNovartis AG_x000D_ Recent Developments
10.11 Kite Pharma, Inc_x000D_
10.11.1 Kite Pharma, Inc_x000D_ Basic Information
10.11.2 Kite Pharma, Inc_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.11.3 Kite Pharma, Inc_x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.11.4 Kite Pharma, Inc_x000D_ Business Overview
10.11.5 Kite Pharma, Inc_x000D_ Recent Developments
10.12 Spectrum Pharmaceuticals, Inc._x000D_
10.12.1 Spectrum Pharmaceuticals, Inc._x000D_ Basic Information
10.12.2 Spectrum Pharmaceuticals, Inc._x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.12.3 Spectrum Pharmaceuticals, Inc._x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.12.4 Spectrum Pharmaceuticals, Inc._x000D_ Business Overview
10.12.5 Spectrum Pharmaceuticals, Inc._x000D_ Recent Developments
10.13 Teva Pharmaceutical lndustries Ltd._x000D_
10.13.1 Teva Pharmaceutical lndustries Ltd._x000D_ Basic Information
10.13.2 Teva Pharmaceutical lndustries Ltd._x000D_ Adult Non Hodgkin Lymphoma Treatment Product Overview
10.13.3 Teva Pharmaceutical lndustries Ltd._x000D_ Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.13.4 Teva Pharmaceutical lndustries Ltd._x000D_ Business Overview
10.13.5 Teva Pharmaceutical lndustries Ltd._x000D_ Recent Developments
10.14 Bristol Myers Squibb Company
10.14.1 Bristol Myers Squibb Company Basic Information
10.14.2 Bristol Myers Squibb Company Adult Non Hodgkin Lymphoma Treatment Product Overview
10.14.3 Bristol Myers Squibb Company Adult Non Hodgkin Lymphoma Treatment Product Market Performance
10.14.4 Bristol Myers Squibb Company Business Overview
10.14.5 Bristol Myers Squibb Company Recent Developments
11 Adult Non Hodgkin Lymphoma Treatment Market Forecast by Region
11.1 Global Adult Non Hodgkin Lymphoma Treatment Market Size Forecast
11.2 Global Adult Non Hodgkin Lymphoma Treatment Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Adult Non Hodgkin Lymphoma Treatment Market Size Forecast by Country
11.2.3 Asia Pacific Adult Non Hodgkin Lymphoma Treatment Market Size Forecast by Region
11.2.4 South America Adult Non Hodgkin Lymphoma Treatment Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Adult Non Hodgkin Lymphoma Treatment by Country
12 Forecast Market by Type and by Application (2026-2033)
12.1 Global Adult Non Hodgkin Lymphoma Treatment Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Adult Non Hodgkin Lymphoma Treatment by Type (2026-2033)
12.1.2 Global Adult Non Hodgkin Lymphoma Treatment Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Adult Non Hodgkin Lymphoma Treatment by Type (2026-2033)
12.2 Global Adult Non Hodgkin Lymphoma Treatment Market Forecast by Application (2026-2033)
12.2.1 Global Adult Non Hodgkin Lymphoma Treatment Sales (K MT) Forecast by Application
12.2.2 Global Adult Non Hodgkin Lymphoma Treatment Market Size (M USD) Forecast by Application (2026-2033)
13 Conclusion and Key Findings
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.